Autoinflammation in 2010: Expanding clinical spectrum and broadening therapeutic horizons

Nature Reviews Rheumatology

Volumn 7, Issue 2, 2011, Pages 82-84

  Ombrello, Michael J ^a   Kastner, Daniel L ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID P;

AMYLOIDOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CLINICAL RESEARCH; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; INFLAMMATORY INFILTRATE; INJECTION SITE REACTION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; MUCKLE WELLS SYNDROME; MUTATIONAL ANALYSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

AMYLOIDOSIS; ANIMALS; ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1;

EID: 79551698672     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.229     Document Type: Review

References (10)

1. Kastner, D. L., aksentijevich, i. & Goldbach- Mansky, r. autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784-790 (2010).
2. Masters, S. L., Simon, a., aksentijevich, i. & Kastner, D. L. Horror autoinflammaticus: the molecular pathology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
3. neven, B. et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62, 258-267 (2010).
4. Lepore, L. et al. Follow-up and quality of life of patients with cryopyrin-asociated periodic syndromes treated with anakinra. J. Pediatr. 157, 310-315 (2010).
5. Bodin, K. et al. antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 90-97 (2010).
6. Duewell, P. et al. nLrP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
7. Goldbach-Mansky, r. Blocking interleukin-1 in rheumatic diseases. Ann. NY Acad. Sci. 1182, 111-123 (2009).
8. Kubota, T. & Koike, r. Cryopyrin-associated periodic syndromes: background and therapeutics. Mod. Rheumatol. 20, 213-221 (2010).
9. Lachmann, H. J. (Pubitemid 46883770)
10. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002). (Pubitemid 34534701)